INNOVATIONS IN DIAGNOSTICS AND TREATMENT OF PATIENTS WITH HYPERTRIGLYCERIDEMIA


Cite item

Full Text

Abstract

This article presents innovative techniques for diagnostics, risk stratification and treatment of patients with hypertriglyceridemia. Hypertriglyceridemia is not only known as an independent risk factor of cardiovascular diseases, but also its high level can become a cause of acute pancreatitis.

About the authors

VV V Simerzin

Samara State Medical University

Email: simerzi@mail.ru
PhD, professor of the Faculty Therapy Department, Samara State Medical University 89 Chapaevskaya st Samara, Russia, 443099

OV V Fatenkov

Samara State Medical University

Email: kdmc@mail.ru
PhD, Associate Professor, head of the Faculty Therapy Department, Samara State Medical University

IV V Gagloeva

Samara State Medical University

Email: gagloeva@samtfoms.ru
PhD, chief specialist of the Territorial Compulsory Medical Insurance Fund of Samara region

MA A Galkina

Samara State Medical University

Email: mkmkmk1977@mail.ru
teaching assistant of the Faculty Therapy Department, Samara State Medical University

YaA A Panisheva

Samara State Medical University

Email: jana.panisheva@mail.ru
therapeutist of the Clinics of Faculty Therapy of Samara State Medical University

MA A Krasovskaya

Samara State Medical University

Email: geliosmax@yandex.ru
resident physician of the Clinics of Samara State Medical University

References

  1. Shi Y, Cheng D. Beyond triglyceride synthesis: the dynamic functional roles of MGAT and DGAT enzymes in energy metabolism. Am J Physiol Endocrinol Metab. 2009; 297 (1): E10-8. doi: 10.1152/ajpendo.90949.2008
  2. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo controlled trial THE LANCET. Vol 360. July 6, 2002. www.thelancet.com
  3. Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, Boekholdt SM, Ouwehand W, Watkins H, Samani NJ, Saleheen D, Lawlor D, Reilly MP, Hingorani AD, Talmud PJ, Danesh J. Triglyceride- mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010;375:1634-1639. doi: 10.1016/S0140-6736(10)60545-4
  4. Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Boren J, Catapano AL, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Nordestgaard BG, Ray KK, Reiner Z, Taskinen MR, Tokgozoglu L, Tybjaerg-Hansen A, Watts GF;, and the European Atherosclerosis Society Consensus Panel. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011; 32: 1345-61. doi: 10.1093/ eurheartj/ehr112. Epub 2011 Apr 29
  5. Talayero BG, Sacks FM. The role of triglycerides in atherosclerosis. Curr Cardiol Rep. 2011; 13 (6): 544-52. doi: 10.1007/s11886-011-0220-3
  6. Brahm A, Hegele RA. Hypertriglyceridemia. Nutrients. 2013, 5 (3): 981-1001. doi: 10.3390/nu5030981
  7. Robert A Hegele, Henry N Ginsberg, M John Chapman, Borge G Nordestgaard, Jan Albert Kuivenhoven, Maurizio Averna, Jan Boren, Eric Bruckert, Alberico L Catapano, Olivier S Descamps, G Kees Hovingh, Steve E Humphries, Petri T Kovanen, Luis Masana, Paivi Pajukanta, Klaus G Parhofer, Frederick J Raal, Kausik K Ray, Raul D Santos, Anton F H Stalenhoef, Erik Stroes, Marja-Riitta Taskinen, Anne Tybjsrg-Hansen, Gerald F Watts, Olov Wiklund. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol 2014 (2): 655-666. www.thelancet.com/diabetes-endocrinology. doi: 10.1016/S2213-8587(13)70191-8
  8. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97
  9. Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Perrone Filardi P, Riccardi G, Storey RF, Wood D. Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), and the ESC Committee for Practice Guidelines 2008-2010 and 2010-2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011; 217 (suppl 1): S1-44). doi: 10.1016/j.atherosclerosis.2011.06.012
  10. Berglund L, Brunzell JD, Goldberg AC, Goldberg IJ, Sacks F, Murad MH, Stalenhoef AF. Endocrine Society. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012; 97: 2969-89.doi: 10.1210/jc.2011-3213
  11. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, Boekholdt SM, Khaw KT, Gudnason V.Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262 525 participants in 29 Western prospective studies. Circulation 2007; 115: 450-58
  12. Sarwar N, Sattar N. Triglycerides and coronary heart disease: have recent insights yielded conclusive answers? Curr Opin Lipidol 2009; 20: 275-81.doi: 10.1097/ MOL.0b013e32832dd4dc
  13. Morrison A, Hokanson JE. The independent relationship between triglycerides and coronary heart disease. Vasc Health Risk Manag. 2009;5(1):89-95. E-pub 2009 Apr 8
  14. Austin MA, Hokanson JE, Edwards KL Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998;81:7B-12B
  15. Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ, 2007, 176: 1113-20
  16. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D, and the European Association for Cardiovascular Prevention & Rehabilitation, and the ESC Committee for Practice Guidelines (CPG) 20082010 and 2010-2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011, 32: 1769-818. doi: 10.1093/eurheartj/ ehr158
  17. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA, 2007; 298: 299-308
  18. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA 2008, 300: 2142-52.doi: 10.1001/ jama.2008.621
  19. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorolo K, Keil U; EUROASPIRE Study Group. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009;16:121-137
  20. Bansal S1, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007 Jul 18;298(3):309-16
  21. The ACCORD Study Group. Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. N Engl J Med 2010. Published on March 14, 2010, updated on March 18, 2010, at NEJM.org. doi: 10.1056/NEJMoa1001282
  22. Assmann G, MD, FRCP; Cullen P, MD, FRCPI; Schulte H, PhD. Simple Scoring Scheme for Calculating the Risk of Acute Coronary Events Based on the 10-Year Follow-Up of the Prospective Cardiovascular Munster (PROCAM) Study. Downloaded from http://circ.ahajournals.org/ Downloaded from/ by guest on January 4, 2017
  23. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J. Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009 Nov 11;302(18):1993-2000. PubMed PMID: 19903920. doi: 10.1001/jama.2009.1619
  24. Varbo A, Benn M, Tybjorg-Hansen A, Jorgensen AB, Frikke Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 2013; 61: 427-36. doi: 10.1016/j.jacc.2012.08.1026
  25. Jorgensen AB, Frikke-Schmidt R, West AS, Grande P, Nordestgaard BG, Tybjsrg-Hansen A. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J 2013; 34: 1826-33. doi: 10.1093/eurheartj/ehs431
  26. Anderson TJ, Gregoire J, Hegele RA, Couture P, Mancini GB, McPherson R, Francis GA, Poirier P, Lau DC, Grover S, Genest J Jr, Carpentier AC, Dufour R, Gupta M, Ward R, Leiter LA, Lonn E, Ng DS, Pearson GJ, Yates GM, Stone JA, Ur E. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2013; 29: 151-67. doi: 10.1016/j. cjca.2012.11.032
  27. NIH-NCEP. Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Executive Summary. 2004; NIH. Nugent AP. LIPGENE: an EU project to tackle the metabolic syndrome. Biochimie. 2005; 87 (1):129-32
  28. Кухарчук В.В., Коновалов Г.А., Гапявич А.С. Диагностика и коррекция нарушений липидного обмена с цепью профилактики и печения атеросклероза. Российские рекомендации пересмотр. М., 2012
  29. Morrone D, Weintraub WS, Toth PP, et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis 2012; 223: 251-61
  30. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R, and the Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78
  31. Boekholdt SM, Arsenault BJ, Mora S, Pedersen TR, LaRosa JC, Nestel PJ, Simes RJ, Durrington P, Hitman GA, Welch KM, DeMicco DA, Zwinderman AH, Clearfieldo MB, Downs JR, Tonkin AM, Colhoun HM, Gotto AM Jr, Ridker PM, Kastelein JJ.Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 2012; 307: 1302-09. doi: 10.1001/ jama.2012.366
  32. Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, de Graaf J, Furberg CD. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 2011; 4: 337-45. doi: 10.1161/CIRCOUTCOMES.110.959247
  33. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998; 98: 2088-93
  34. Michos ED, Sibley CT, Baer JT, Blaha MJ, Blumenthal RS. Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial with previous surrogate endpoint trials. J Am Coll Cardiol, 59 (2012): 2058-2064
  35. Kamanna V.S., Kashyap M.L. Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents? Am J Cardiol 2007(100):53-61
  36. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-381
  37. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-2267. doi: 10.1056/NEJMoa1107579
  38. Guyton JR, Slee AE, Anderson T, Fleg JL, Goldberg RB, Kashyap ML, Marcovina SM, Nash SD, O'Brien KD, Weintraub WS, Xu P, Zhao XQ, Boden WE. Relationship of lipoproteins to cardiovascular events in the atherothrombosis intervention in metabolic syndrome with low HDL/high triglycerides and impact on global health outcomes (AIM-HIGH) trial. J Am Coll Cardiol 2013;62(17):1580-1584. doi: 10.1016/j. jacc.2013.07.023
  39. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013;34(17):1279-1291)
  40. Gotoda T, Shirai K, Ohta T, Kobayashi J, Yokoyama S, Oikawa S, Bujo H, Ishibashi S, Arai H, Yamashita S, Harada-Shiba M, Eto M, Hayashi T, Sone H, Suzuki H, Yamada N; Research Committee for Primary Hyperlipidemia. Diagnosis and management of type I and type V hyperlipoproteinemia. J Atheroscler Thromb. 2012; 19 (1):1-12
  41. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013;34(17):1279-1291
  42. University of Oxford Clinical Trial Service Unit and Epidemiological Studies Unit. HPS2-THRIVE. http://www. ctsu.ox.ac.uk/research/mega-trials/hps2-thrive (accessed Nov 28, 2013)
  43. Huijgen R, Abbink EJ, Bruckert E, Stalenhoef AF, Imholz BP, Durrington PN, Trip MD, Eriksson M, Visseren FL, Schaefer JR, Kastelein JJ, and the Triple Study Group. Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12 week, multicenter, randomized, double-blind, controlled trial. Clin Ther 2010; 32: 615-25. doi: 10.1016/j.clinthera
  44. Erik S. Stroes; Paul D. Thompson; Alberto Corsini; Georgirene D. Vladutiu; Frederick J. Raal; Kausik K. Ray; Michael Roden; Evan Stein; Lale Tokgozoglu; Borge G. Nordestgaard; Eric Bruckert; Guy De Backer; Ronald M. Krauss; Ulrich Laufs; Raul D. Santos; Robert A. Hegele; Hovingh G. Kees; Lawrence A. Leiter; Francois Mach; Winfried Marz; Connie B. Newman; Olov Wiklund; Terry A. Jacobson; Alberico L. Catapano; M. John Chapman; Henry N. Ginsberg European Atherosclerosis Society Consensus Panel; European Atherosclerosis Society Consensus Panel; Erik Stroes; Paul D. Thompson; Alberto Corsini; Georgirene D. Vladutiu; Frederick J. Raal; Kausik K. Ray; Michael Roden; Evan Stein; Lale Tokgozoglu; Borge G. Nordestgaard; Eric Bruckert; Ronald M. Krauss; Ulrich Laufs; Raul D. Santos; Winfried Marz; Connie B. Newman; M. John Chapman; Henry N. Ginsberg; M. John Chapman; Henry N. Ginsberg; Guy de Backer; Alberico L. Catapano; Robert A. Hegele; G. Kees Hovingh; Terry A. Jacobson; Lawrence Leiter; Francois Mach Olov Wiklund. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J (2015) 36 (17): 1012-1022. DOI: https://doi.org/10.1093/eurheartj/ehv043
  45. Brunzell JD, Miller NE, Alaupovic P, Hilaire R.J.St, Wang C.S, David L. hn, Bloom SR, and Lewis B. Familial chylomicronemia due to a circulating inhibitor of lipoprotein lipase activity. Journal of Lipid Research. 1983; 24 (1): 12 19
  46. Santamarina-Fojo S. The familial chylomicronemia syndrome. Endocrinology and Metabolism Clinics of North America. 1998; 27 (3):551-567
  47. Leaf DA. Chylomicronemia and the chylomicronemia syndrome: a practical approach to management. Am J Med. 2008; 121 (1): 10-2. doi: 10.1016/j.amjmed
  48. Gaddi A, Cicero AF, Odoo FO, Poli AA, Paoletti R; Atherosclerosis and Metabolic Diseases Study Group. Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date. Vasc Health Risk Manag. 2007; 3 (6):877-86
  49. Gotoda T, Shirai K, Ohta T, Kobayashi J, Yokoyama S, Oikawa S, Bujo H, Ishibashi S, Arai H, Yamashita S, Harada-Shiba M, Eto M, Hayashi T, Sone H, Suzuki H, Yamada N. Research Committee for Primary Hyperlipidemia. Diagnosis and management of type I and type V hyperlipoproteinemia. J Atheroscler Thromb. 2012; 19 (1):1-12

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Simerzin V.V., Fatenkov O.V., Gagloeva I.V., Galkina M.A., Panisheva Y.A., Krasovskaya M.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».